Sehn LH - Search Results

1

Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.

Hilton LK, Ngu HS, Collinge B, Dreval K, Ben-Neriah S, Rushton CK, Wong JCH, Cruz M, Roth A, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Gerrie AS, Freeman CL, Villa D, Rodrigo JA, Song K, Crump M, Shepherd L, Hay AE, Kuruvilla J, Savage KJ, Kridel R, Karsan A, Marra MA, Sehn LH, Steidl C, Morin RD, Scott DW. Hilton LK, et al. Among authors: sehn lh. J Clin Oncol. 2023 Sep 1;41(25):4164-4177. doi: 10.1200/JCO.23.00570. Epub 2023 Jun 15. J Clin Oncol. 2023. PMID: 37319384 Free PMC article.

2

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM. Sehn LH, et al. J Clin Oncol. 2005 Aug 1;23(22):5027-33. doi: 10.1200/JCO.2005.09.137. Epub 2005 Jun 13. J Clin Oncol. 2005. PMID: 15955905

3

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.

Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, Powers J, Wright J, Eisenhauer EA. Belch A, et al. Ann Oncol. 2007 Jan;18(1):116-121. doi: 10.1093/annonc/mdl316. Epub 2006 Sep 13. Ann Oncol. 2007. PMID: 16971665 Free article. Clinical Trial.

4

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM. Sehn LH, et al. Blood. 2007 Mar 1;109(5):1857-61. doi: 10.1182/blood-2006-08-038257. Epub 2006 Nov 14. Blood. 2007. PMID: 17105812 Free article.

5

LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.

Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS. Natkunam Y, et al. Among authors: sehn lh. J Clin Oncol. 2008 Jan 20;26(3):447-54. doi: 10.1200/JCO.2007.13.0690. Epub 2007 Dec 17. J Clin Oncol. 2008. PMID: 18086797

6

Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.

Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM. Al-Tourah AJ, et al. Among authors: sehn lh. J Clin Oncol. 2008 Nov 10;26(32):5165-9. doi: 10.1200/JCO.2008.16.0283. Epub 2008 Oct 6. J Clin Oncol. 2008. PMID: 18838711

7

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.

Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, Sehn LH, Chhanabhai M, Brinkman RR, Connors JM, Weng AP, Gascoyne RD. Johnson NA, et al. Among authors: sehn lh. Blood. 2009 Apr 16;113(16):3773-80. doi: 10.1182/blood-2008-09-177469. Epub 2008 Nov 24. Blood. 2009. PMID: 19029441 Free PMC article.

8

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.

Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD. Savage KJ, et al. Among authors: sehn lh. Blood. 2009 Oct 22;114(17):3533-7. doi: 10.1182/blood-2009-05-220095. Epub 2009 Aug 24. Blood. 2009. PMID: 19704118 Free article.

9

Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.

Shustik J, Han G, Farinha P, Johnson NA, Ben Neriah S, Connors JM, Sehn LH, Horsman DE, Gascoyne RD, Steidl C. Shustik J, et al. Among authors: sehn lh. Haematologica. 2010 Jan;95(1):96-101. doi: 10.3324/haematol.2009.007203. Epub 2009 Oct 1. Haematologica. 2010. PMID: 19797725 Free PMC article.

10

Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).

Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Shyam R, Horning S, Sehn LH, Farinha P, Briones J, Lossos IS, Gascoyne RD, Natkunam Y. Gratzinger D, et al. Among authors: sehn lh. Br J Haematol. 2010 Jan;148(2):235-44. doi: 10.1111/j.1365-2141.2009.07942.x. Epub 2009 Oct 11. Br J Haematol. 2010. PMID: 19821819 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

255 results

Search Page

Filters